Meta Information
ID:betaine
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-21T22:30:00Z
Model
phase-a-upgrade-claude-sonnet-4.6
Interactions
Target id:
/intervention/nmn
Target name:
Nicotinamide Mononucleotide (NMN)
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
NMN consumes methyl groups during its metabolism, which can deplete the body's reserves and increase homocysteine. Betaine provides methyl groups to replenish this pool, preventing potential side effects.
Actionable advice:
Betaine is best taken concurrently with NMN, often at a 1:1 or 1:2 dose ratio (Betaine:NMN).
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Biochemical inference: NMN/NAD+ turnover routes through NNMT, which methylates nicotinamide using SAM and can raise homocysteine; betaine (via BHMT) remethylates homocysteine to replenish methyl groups. Well-established biochemistry; the NMN-specific limb is not in the cited PMID 27207152 (which covers the remethylation half only).
Label source:
Class inference
Action type:
informational_none
Target id:
/intervention/nr
Target name:
Nicotinamide Riboside (NR)
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
NR consumes methyl groups during its metabolism, which can deplete the body's reserves and increase homocysteine. Betaine provides methyl groups to replenish this pool, preventing potential side effects.
Actionable advice:
Betaine is best taken concurrently with NR, often at a 1:1 or 1:2 dose ratio (Betaine:NR).
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Exact phrase from label:
Excess NAM that is not recycled is metabolized through two enzymatic systems and eventually excreted from the body.55 The first system methylates the NAM into MNAM by NNMT, which utilizes the SAM as methyl donor.
Label source:
Action type:
informational_none
Target id:
/class/b-vitamins-homocysteine
Target name:
Folate (B9), Vitamin B12, and Vitamin B6
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Betaine, Folate, B12, and B6 all participate in different pathways to lower homocysteine. Their combined action provides comprehensive support for the methylation cycle.
Actionable advice:
Adequate intake of key B-vitamins is a good idea when using Betaine for homocysteine management.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Mechanistic inference: betaine (trimethylglycine) remethylates homocysteine via BHMT while folate/B12/B6 act through methionine synthase and transsulfuration; combined use lowers homocysteine additively. Established biochemistry - complementary, not adverse.
Label source:
Class inference
Action type:
informational_none
Target id:
/intervention/methotrexate
Target name:
Methotrexate
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Methotrexate works by inhibiting folate metabolism, which raises homocysteine. While Betaine can lower homocysteine, it may interfere with methotrexate's therapeutic effects and should only be used under strict medical guidance. However at this time there is no evidence that Betaine interferes with methotrexate treatment.
Actionable advice:
Betaine should not be taken with Methotrexate unless specifically directed and monitored by a physician.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
These data suggest that the betaine lowering seen in livers of choline-fed rats may be due to utilization as a means of compensating for the MTX-induced loss of N5 methyltetrahydrofolate for the vital methylation of homocysteine in methionine biosynthesis.
Label source:
PubMed: Drug-nutrient interactions (1982)
Source url:
Exact phrase from label:
This effect can be partially achieved when methionine is replaced by choline or betaine. No alteration in the formation of 7-hydroxymethotrexate could be detected by similar changes in methionine concentrations in the medium.
Label source:
PubMed: Biochimica et biophysica acta (1989)
Source url:
Exact phrase from label:
These data suggest that betaine may compensate for N5 methyltetrahydrofolate as a methylating substance when folate metabolism is antagonized in rat liver.
Label source:
PubMed: Drug-nutrient interactions (1982)
Action type:
avoid
Target id:
/condition/renal-impairment
Target name:
Renal Impairment
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Betaine and its metabolites are cleared by the kidneys. In cases of moderate to severe kidney disease, clearance may be reduced, leading to accumulation and potential side effects.
Actionable advice:
It is important to consult a physician before using Betaine for those with known kidney disease.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Mechanistic inference: betaine-pathway metabolites (incl. TMAO) are renally cleared, so accumulation is plausible in moderate-severe kidney disease. Indirect support (cited PMID 29915157 is a TMAO mouse-CKD model, not betaine itself) -> class inference.
Label source:
Class inference
Action type:
informational_none
Target id:
/condition/cerebral-edema
Target name:
Cerebral Edema
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
As a potent osmolyte, Betaine can alter cellular water balance. In the presence of cerebral edema (brain swelling), it is contraindicated as it may exacerbate fluid shifts and worsen the condition.
Actionable advice:
Betaine should not be taken with, or at acute risk for, cerebral edema.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
We conclude that the cerebral edema was most likely precipitated by the betaine therapy, although the exact mechanism is uncertain. This case cautions physicians to monitor methionine levels in CBS-deficient patients on betaine and to consider betaine as an adjunct, not an alternative, to dietary control.
Label source:
PubMed: American journal of medical genetics (2002)
Source url:
Exact phrase from label:
Betaine does raise the methionine level and cerebral edema has occurred when plasma methionine exceeds 1000 micromol/L. Thus the plasma methionine as well as homocysteine must be monitored in patients receiving betaine.
Label source:
PubMed: Molecular genetics and metabolism (2006)
Source url:
Exact phrase from label:
We conclude that, while betaine supplementation does greatly exacerbate methionine accumulation, the primary agent causing brain edema is methionine rather than betaine.
Label source:
PubMed: JIMD reports (2020)
Action type:
avoid
Target id:
/condition/homocystinuria
Target name:
Homocystinuria
Severity:
major
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Betaine is an FDA-approved medical treatment for homocystinuria, a genetic disorder causing dangerously high homocysteine levels. It works by providing an alternative pathway to convert homocysteine back to methionine.
Actionable advice:
This should be used as prescribed by a physician for the treatment of homocystinuria.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Here we review the use of betaine to decrease these elevated levels of homocysteine back to within normal ranges.
Label source:
PubMed: Frontiers in nutrition (2021)
Source url:
Exact phrase from label:
Betaine is a methyl donor agent that is beneficial in lowering homocysteine through the remethylation of methionine.
Label source:
PubMed: Molecular genetics and metabolism (2006)
Source url:
Exact phrase from label:
Ten patients with cystathionine beta-synthase deficiency that was not responsive to pyridoxine and one patient with homocystinuria due to a defect in cobalamin metabolism were treated with 6 g daily of betaine added to conventional therapy, to improve homocysteine remethylation.
Label source:
PubMed: The New England journal of medicine (1983)
Action type:
informational_none
Target id:
/biomarker/lipid-panel
Target name:
Lipid Panel (Cholesterol)
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
In some individuals, particularly at higher doses, Betaine supplementation has been associated with a modest increase in LDL and total cholesterol levels.
Actionable advice:
It is a good idea to check a lipid panel periodically when taking high-dose or long-term Betaine.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Betaine supplementation had a significant effect on concentrations of betaine (MD: 82.14 μmol/L, 95% CI: 67.09 to 97.20), total cholesterol (TC) (MD: 14.12 mg/dl, 95% CI%: 9.23 to 19.02), low-density lipoprotein (LDL) (MD: 10.26 mg/dl, 95% CI: 6.14 to 14.38)], homocysteine (WMD: -1.30 micromol/L, 95% CI: -1.61 to -0.98), dimethylglycine (DMG) (MD: 21.33 micromol/L, 95% CI: 13.87 to 28.80), and methionine (MD: 2.06 micromol/L, 95% CI: 0.23 to 3.88).
Label source:
PubMed: Effects of betaine supplementation on cardiovascular markers: A systematic review and Meta-analysis. (PMID 33764214)
Action type:
monitor
Target id:
/biomarker/creatinine
Target name:
Serum Creatinine
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Betaine can increase the body's own production of creatine, which breaks down into creatinine. This may cause a slight, benign elevation in serum creatinine that reflects increased muscle creatine stores, not kidney damage.
Actionable advice:
It is generally best to let a doctor know about Betaine use if creatinine levels are being monitored.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Physiological inference: betaine supports endogenous creatine synthesis; more creatine turnover yields more creatinine, producing a small benign serum-creatinine rise that reflects muscle stores, not nephrotoxicity. Textbook; the cited PMID 27207152 does not directly measure creatinine.
Label source:
Class inference
Action type:
monitor
Target id:
/intervention/creatine
Target name:
Creatine
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Betaine supports the body's natural synthesis of creatine from glycine and arginine. Taking them together may have an additive effect on increasing muscle creatine stores and performance.
Actionable advice:
Consider that Betaine contributes to creatine synthesis when planning your creatine dosage.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
when methionine is limiting, supplementation with either folate or betaine leads to higher methionine availability for protein synthesis.
Label source:
Methionine-metabolism thesis, PMID 27207152. Supports betaine sparing methionine (creatine synthesis is a major methyl sink). Note: the additive-with-supplemental-creatine specific is an extension of the methyl-donor mechanism.
Action type:
informational_none
Target id:
/intervention/sam-e
Target name:
SAM-e (S-adenosylmethionine)
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Betaine helps regenerate methionine, which is the direct precursor to SAM-e. Taking both can provide comprehensive support for methylation, though high doses of both may be redundant.
Actionable advice:
Caution may help with combined high doses; it is worth monitoring for effects of over-methylation if applicable.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
homocysteine is formed, which can be converted to cysteine via transsulfuration or remethylated to methionine by receiving a methyl group from folate or betaine.
Label source:
Methionine-metabolism thesis, PMID 27207152. Supports betaine regenerating methionine, the direct SAM-e precursor; combined methylation support (may be redundant at high doses).
Action type:
monitor
Target id:
/intervention/niacin
Target name:
Niacin (High Dose)
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
High-dose niacin therapy consumes a large number of methyl groups for its metabolism. Betaine can supply these methyl groups, potentially reducing side effects and maintaining healthy homocysteine levels.
Actionable advice:
Taking Betaine concurrently is a good idea on a high-dose niacin protocol.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Diabetic or potentially diabetic patients should be observed closely during treatment with niacin extended-release tablets, particularly during the first few months of use or dose adjustment; adjustment of diet and/or hypoglycemic therapy may be necessary.
Label source:
Action type:
informational_none
Target id:
/class/fibrates
Target name:
Fibrates
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Fibrate medications (e.g., fenofibrate) used for managing triglycerides can increase homocysteine levels. Betaine effectively counteracts this increase by promoting the remethylation of homocysteine.
Actionable advice:
Consider adding Betaine if you are taking a fibrate and have elevated homocysteine.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Combination therapy was associated with higher elevations in homocysteine, blood urea nitrogen, and serum creatinine, whereas elevation in alanine aminotransferase was greater in the rosuvastatin group.
Label source:
RCT, PMID 22269152. Supports the fenofibrate-containing regimen raising homocysteine; betaine's remethylation counteracts this (established, not tested in this trial).
Action type:
informational_none
Target id:
/intervention/choline
Target name:
Choline
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Choline is a precursor to Betaine in the body. Supplementing both supports the same metabolic pathways related to methylation and liver health, though high doses of both may be unnecessary.
Actionable advice:
Choline and Betaine have overlapping functions when both are dosed.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
It, or its metabolites, assures the structural integrity and signaling functions of cell membranes; it is the major source of methyl-groups in the diet (one of choline's metabolites, betaine, participates in the methylation of homocysteine to form methionine); and it directly affects nerve signaling, cell signaling and lipid transport/metabolism.
Label source:
PubMed: Choline: needed for normal development of memory. (PMID 11023003)
Action type:
informational_none